Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Q32 Bio Inc. (QTTB : NSDQ)

• Company Description    Q32 Bio Inc. is a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Q32 Bio Inc., formerly known as Homology Medicines Inc., is based in WALTHAM, Mass. Number of Employees: 42

• Price / Volume Information    Yesterday's Closing Price: $3.32 Daily Weekly Monthly 20 Day Moving Average: 3,093,297 shares Shares Outstanding: 12.20 (millions) Market Capitalization: $40.50 (millions) Beta: -0.07 52 Week High: $53.79 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 95.29% 87.98% 12 Week 56.60% 31.73% Year To Date -3.49% -9.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 781-999-0232 fax: - q32bio@argotpartners.com http://www.q32bio.com

• General Corporate Information    Officers Jodie Morrison - Chief Executive Officer Lee Kalowski - Chief Financial Officer and President David Grayzel - Director Diyong Xu - Director Isaac Manke - Director Peer Information Q32 Bio Inc. (CORR.) Q32 Bio Inc. (RSPI) Q32 Bio Inc. (CGXP) Q32 Bio Inc. (BGEN) Q32 Bio Inc. (GTBP) Q32 Bio Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 746964105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 12.20 Most Recent Split Date: 3.00 (0.06:1) Beta: -0.07 Market Capitalization: $40.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 93.16% vs. Previous Quarter: 22.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -447.33 12/31/24 - -239.52 ROA 06/30/25 - - 03/31/25 - -59.77 12/31/24 - -53.76 Current Ratio 06/30/25 - - 03/31/25 - 4.71 12/31/24 - 4.97 Quick Ratio 06/30/25 - - 03/31/25 - 4.71 12/31/24 - 4.97 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.33 12/31/24 - 0.47 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 1.68 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 62.74

Powered by Zacks Investment Research ©